Antitumor effects of rhodium (II) complexes on mice bearing Ehrlich tumors
Braz. j. med. biol. res
;
27(1): 91-4, jan. 1994. tab
Article
Dans Anglais
| LILACS
| ID: lil-136497
ABSTRACT
Rhodium (II) trifluoracetate (TFARh), rhodium (II) trifluoracetate adduct with sulfadiazine (TFARh.Sd) and rhodium (II) acetate adduct with sulfisoxazole (RhSx) were tested in mice for acute toxicity, antitumoral activity against Ehrlich ascites carcinoma and for viability of Ehrlich tumor cells in culture. At ip doses up to 60 µmg/kg (40-70 and 59 mg/kg, respectively), these coumpounds had no toxic effects up to 14 days. At ip doses of 10 µmol Kg-1 day-1 for 5 days, TFARh and TFARh.Sd significantly increased the survival rate of mice bearing Ehrlich ascites cells (probability of survival to the end of 34th day, controls = 0.23, TFARh = 0.85, TFARh.Sd = 0.74). No significant effect was observed for RhSx. In vitro, these rhodium complexes at 40 µM significantly increased the number of dead cells in cultured Ehrlich tumor cells
Recherche sur Google
Indice:
LILAS (Amériques)
Sujet Principal:
Rhodium
/
Techniques in vitro
/
Carcinome d'Ehrlich
/
Protocoles de polychimiothérapie antinéoplasique
Limites du sujet:
Animaux
langue:
Anglais
Texte intégral:
Braz. j. med. biol. res
Thème du journal:
Biologie
/
Médicament
Année:
1994
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS